Bristol-Myers Beats Celgene Investors' Drug Delay Suit

By Lauren Berg · September 30, 2024, 9:24 PM EDT

A New York federal judge on Monday tossed UMB Bank's claims that Bristol-Myers Squibb improperly delayed U.S. Food and Drug Administration approval of a cancer treatment to avoid paying shareholders $6.4...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

UMB Bank, N.A. v. Bristol-Myers Squibb Company

Case Number

Court

New York Southern

Nature of Suit

Contract: Other

Date Filed

June 02, 2021

Recent Articles By Lauren

November 20, 2024
Musk, Ramaswamy Say High Court Rulings OK Federal Cuts
November 15, 2024
Eli Lilly Says HHS Ignores Drug Discount Double-Dipping
November 12, 2024
J&J Says HHS Is Thwarting Transparency Of Drug Discounts
October 30, 2024
FDA Didn't Flub Approval In Orphan Drug Case, DC Court Says
October 18, 2024
Oklahoma Brings Title X Funding Cut Fight To Justices
October 11, 2024
Feds Target Ill. Hospital CEO As $19M Theft Probe Widens
October 11, 2024
Quinn Emanuel Gets Trimmed $92M Fee In ACA Cases
September 30, 2024
Takeda End Payors, Direct Buyers Win Antitrust Class Cert.
September 27, 2024
9th Circ. Says Stem Cell Treatment Not Exempt From FDA Rule
August 30, 2024
McKesson, Others To Pay Benefit Plans $300M In Opioid Deal